Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9845447 | 0.90 | KMO (0.62) | KMOTSHRHTTALDH1A1GAA | |
| SCHEMBL16897901 | 0.84 | TSHR (0.76) | KMOTSHRHTTALDH1A1GAA | |
| SCHEMBL18259130 | 0.84 | KMO (1.00) | KMOTSHRHTTALDH1A1MEN1 | |
| SCHEMBL4052063 | 0.81 | GAA (0.49) | KMOTSHRHTTALDH1A1GAA | |
| SCHEMBL7279865 | 0.81 | KMO (0.68) | KMOTSHRHTTALDH1A1GAA | |
| SCHEMBL30096013 | 0.81 | ALDH1A1 (0.68) | KMOTSHRALDH1A1GAAMEN1 | |
| SCHEMBL4971763 | 0.81 | ALDH1A1 (0.68) | KMOTSHRALDH1A1GAAMEN1 | |
| SCHEMBL4096802 | 0.80 | KMO (0.50) | KMOTSHRHTTGAAPOLB | |
| SCHEMBL13111737 | 0.79 | HTT (0.50) | KMOTSHRHTTALDH1A1GAA | |
| SCHEMBL4327572 | 0.78 | GAA (0.47) | KMOTSHRHTTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056502-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| EP-2125813-A2 | COMPOUNDS | Glaxo Group Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008116815-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056502-A1 | COMPOUNDS | NRDC, NACA, NAA50 | KMO 2899/4885TSHR 3922/4885HTT 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.